Who: Roche/Ribometrix
What: Roche’s Genentech subsidiary and Ribometrix will team up to discover and develop small molecule drug candidates that can modify...
Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.
Who: Roche/Ribometrix
What: Roche’s Genentech subsidiary and Ribometrix will team up to discover and develop small molecule drug candidates that can modify...
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.